Mechanisms of Dyslipidemia-Induced Erectile Dysfunction: A Narrative Review

A review maps five pathways linking dyslipidemia to ED, then concedes direct evidence for all five is limited

Journal: Frontiers in Endocrinology | Published: 2026-04-22 | Type: Narrative Review | PMID: 42100188 Authors: Luo Dicheng et al. (Beijing University of Chinese Medicine; Xiyuan Hospital, China Academy of Chinese Medical Sciences; University of Rome Tor Vergata) Funding/COI: No funding listed. Authors declare no commercial or financial conflicts of interest.

Summary

This narrative review synthesizes 25 years of literature to argue that dyslipidemia contributes to erectile dysfunction through five interconnected pathways: vascular injury, endocrine disturbance, neurological impairment, oxidative stress, and chronic inflammation. The authors organize these into a theoretical framework but are candid that most of the underlying evidence is indirect — drawn from systemic cardiovascular and metabolic studies rather than ED-specific research. The paper is essentially a mechanistic hypothesis generator, not a synthesis of causal evidence.

Claims

• Dyslipidemia promotes endothelial dysfunction by reducing nitric oxide bioavailability and impairing smooth muscle relaxation in the corpus cavernosum
• Elevated LDL and triglycerides, and reduced HDL, are each proposed to independently contribute to penile arterial insufficiency through atherosclerotic remodeling
• Dyslipidemia may suppress testosterone biosynthesis by disrupting cholesterol substrate availability in Leydig cells
• Oxidized LDL is proposed to trigger neuroinflammation and demyelination of cavernous nerves
• Low HDL-C is flagged as an understudied independent variable — animal models do not adequately replicate human low-HDL dyslipidemia, leaving this pathway largely untested
• No quantitative effect estimates are provided; the review is mechanistic, not epidemiological

Study Quality

This is a narrative review with non-exhaustive, non-preregistered study selection — the authors explicitly state inclusion was "prioritized based on relevance, novelty, and mechanistic insight" rather than systematic criteria. There is no PRISMA flow chart, no formal risk-of-bias assessment, and no meta-analytic synthesis. The review integrates findings from animal models, human observational studies, and mechanistic experiments without stratifying by evidence quality. Searching four databases from 2000–2025 in English only is reasonable scope, but the absence of reproducible selection criteria means the literature base could reflect confirmation bias.

The four-domain framework (Vascular, Endocrine, Neurological, Inflammation/Oxidative Stress) is logically organized and the authors are appropriately cautious about causal claims — but a narrative framework built on indirect evidence is a hypothesis, not a finding.

Red Flags

• No systematic selection criteria: cherry-picking risk is not mitigated
• Most cited evidence is from systemic vascular or metabolic studies, not ED-specific endpoints
• Dyslipidemia almost always co-occurs with obesity, insulin resistance, and hyperglycemia; the review acknowledges it cannot isolate dyslipidemia's independent effect, which is the central question it set out to answer
• No quantitative data — no effect sizes, no pooled estimates, nothing to calibrate the magnitude of any claimed mechanism
• Animal models used in the underlying literature do not replicate human low-HDL phenotypes, a gap the authors flag but cannot resolve
• One-sided institutional authorship (TCM-affiliated hospitals) in a context where lipid-lowering drugs and lifestyle interventions would be the obvious clinical implication — worth noting even without declared COI

Strengths

• Authors are unusually honest about the limits of the evidence: they use phrases like "may contribute," "potential mechanisms," and "indirect evidence" consistently rather than overclaiming
• The low-HDL knowledge gap is clearly identified as a research priority, which is a useful pointer for the field
• The call for ED-specific preclinical studies with isolated lipid variables is methodologically sound
• Multi-database search across 25 years covers the relevant mechanistic literature

Verdict

This paper is a well-organized literature map for researchers who want a starting point on dyslipidemia-ED mechanisms — and it earns some credit for not overselling its conclusions. But it contains no new data and no systematic methods. The central limitation the authors identify (inability to isolate dyslipidemia from its metabolic comorbidities) is also the central scientific problem, and the paper does not resolve it. If you already know that vascular health affects erectile function, this review will not surprise you. Its value is in explicitly naming the evidence gaps, particularly around low HDL-C, which appear to be genuinely underresearched.